# Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer

> **NCT02833766** · PHASE2 · TERMINATED · sponsor: **Swiss Cancer Institute** · enrollment: 48 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** anti-EGFR-IL-dox

## Key facts

- **NCT ID:** NCT02833766
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10-28
- **Primary completion:** 2020-10-31
- **Final completion:** 2021-08-03
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** the trial was prematurely terminated as per SAKK board decision from 14th of November 2020. The trial is to be terminated after primary endpoint is reached.
- **Last updated:** 2021-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02833766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02833766, "Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02833766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*